Aktuella utlysningar, vecka 18, 2022
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Kerstin Hejdenbergs stipendium till doktorander
Stipendiet delas ut årligen till doktorander inom barnallergologisk forskning och syftar till att uppmuntra forskning om psykologiska och sociala dimensioner i den allergiska sjukdomen, samt prioritera forskning som kan leda till förbättrad kommunikation mellan vårdpersonal och patient. Fonden stöder gärna tvärvetenskaplig forskning.
Closing date: 25 May 2022
Forskningsanslag - Ollie och Elof Ericssons Stiftelse för Vetenskaplig Forskning
Stiftelsen stöder forskning inom ämnesområdena medicin, teknik och ekonomi. Stiftelsen vänder sig främst till unga, disputerade självständiga forskare som påbörjat uppbyggnaden av egen forskningsverksamhet. Anslagen ligger normalt på mellan 50 000-200 000 kr.
Closing date: 31 May 2022
Sabbatical stay at another university – Karolinska Institutet
To promote research and education at the doctoral level in health care science and strengthen the collaboration between Karolinska Institutet and international research environments in caring science, the strategic research area of health care science (SFO-V) announces funding for sabbatical stays at another university. Eligible to apply are professors and senior lecturers at Karolinska Institutet who:
• Holds permanent employment as professor or senior lecturer at Karolinska Institutet for at least five years.
• Conducts research in one of SFO-V's four main areas.
Closing date: 1 June 2022
Postdoktoralt stipendium – Hjärnfonden
Hjärnfondens stipendium på 300 000 kronor per år avser forskning inom neuroområdet under två år. Fonden stödjer forskning rörande hjärnans och övriga nervsystemets sjukdomar, skador och funktionsnedsättningar, men även den friska hjärnan med dess normala funktioner och utveckling. Stipendierna är öppna för sökande med svensk doktorsexamen och kan tilldelas för studier inom eller utom landet.
Closing date: 7 June 2022
EU4H-2022-PJ EU4Health funding, EU4Health, EU
The European Commission, under its EU4Health programme, invites applications for its funding programme. This supports actions that build resilient and accessible health systems in the EU. Grants are available under the following themes:
•EU4H-2022-PJ-01 – monitor and strengthen the implementation of innovative approaches to prostate, lung and gastric cancer screening at Union level;
•EU4H-2022-PJ-02 – prevention of non-communicable diseases (NCDs), other than cardiovascular diseases and diabetes;
•EU4H-2022-PJ-03 – promoting mental health;
•EU4H-2022-PJ-04 – support the implementation of the regulation on health technology assessment-training of patient and clinical experts contributing to joint health technology assessment activities;
•EU4H-2022-PJ-05 – support increased capacity of notified bodies for medical devices;
•EU4H-2022-PJ-06 – provide training for health workforce, including digital skills;
•EU4H-2022-PJ-07 – support member states and other relevant actors to implement relevant results of innovative public health research in relation to vaccination against COVID-19;
•EU4H-2022-PJ-08 – develop early warning features and guidance in the area of pricing through the EURIPID database, based on competition cases.
Public and private bodies based in the EU, EEA countries or countries associated with the EU4Health programme may apply. Proposals must be submitted by consortia comprising at least three entities from three different eligible countries.
The total budget is €107.3 million, which may be increased by up to 20 per cent. Grants are worth up to €30m to cover up to 80 per cent of eligible costs for between one and three years.
Closing date 24 May 2022, 5pm Brussels time.
Meeting organiser grants
The Federation of European Microbiological Societies invites applications for its meeting organiser grants. These support scientific conferences, laboratory workshops and training courses held in Europe.
A minimum of 60 per cent of the total grant value must be used to support the attendance of early-career scientists.
Grants are worth up to €15,000 each.
Closing date 1 June 2022
Short-term fellowships - European Federation of Immunological Societies
The European Federation of Immunological Societies, together with Immunology Letters, invites applications for their short-term fellowships. These support transnational scientific collaboration and advanced training in techniques or methodologies.
Applicants must be under the age of 35 and hold at least a master’s degree. An extension of the age limit of up to 18 months may be granted for parental leave and civil or military service. Applicants must be members of a society affiliated with EFIS, with an exception made for applicants from European countries without a national society. The proposed stay must be conducted at a European institution.
The fellowship is worth €1,750 per month for up to three months, and includes travel reimbursement of up to €500. The fellowship is not awarded for attendance in courses, symposia, meetings or congresses.
Closing date 29 May 2022
Deadline Information This call is repeated 4 times a year.
The Italian Association for Cancer Research and the Italian Foundation for Cancer Research invite applications for their fellowships in Italy. These enable young graduates or postdoctoral fellows to broaden or acquire experience in oncologic research in a cancer-focused laboratory in Italy. Proposed research should be original, innovative, feasible within the timeframe, and have the potential to advance the field.
Applicants must have a master’s degree or equivalent in medicine, biological sciences, pharmacy, chemistry and pharmaceutical technology, medical statistics, medical biotechnologies or another scientific discipline, obtained after 31 December 2014. They may be of any nationality and are not expected to reside in Italy at the time of the submission deadline. Fellows may not be in receipt of any other continuous employment income during the fellowship period. Fellowships must be undertaken at a research organisation, such as a university, hospital or other research centre in Italy. The IFCR stream also offers mobility fellowships, which provide additional funding to assist fellows who move to a hosting institution located in a different region to their region of origin.
Fellowships are worth €25,000 per year or €30,000 per year in the case of mobility fellowships, for one to three years.
Closing date 7 June 2022 (Forecast)
Coming soon: Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowships 2022
The MSCA 2022 Postdoctoral Fellowships program will open on May 12th after a delay. You can do a postdoc either within Europe with a 2-year fellowship (European Fellowship), or outside Europe (2 years) with a mandatory 1-year return phase to Europe with the 3-year Global Fellowship.
Closing date: 14September 2022
Coming soon: Marie Skłodowska-Curie Actions (MSCA) Doctoral Networks 2022 (former ITN)
The MSCA 2022 Doctoral Networks program will open 12th May, 2022. Principal Investigators participate or coordiantes a Consortium that applies for a training program for PhD students. The PhD students are to be recruited after the project is awarded. The MSCA Doctoral Networks program includes training networks, Industrial Doctorates and Joint Doctorates.
Closing date: 15 November 2022
Federal Funding agencies
Notice of Special Interest: Research on Alcohol and Coronavirus Disease (COVID-19) within the Mission of NIAAA Notice Number: NOT-AA-22-012, US
This Notice of Special Interest (NOSI) solicits grant applications that advance understanding of critical interactions between alcohol use, SARS-CoV-2, and COVID-19. A central focus is research that can improve public health by informing responses to the evolving COVID-19 pandemic and its consequences. NIAAA will support research on risks and outcomes associated with alcohol consumption, SARS-CoV-2 infection, and the COVID-19 pandemic in the general population and among underserved populations, such as racial, ethnic, and sexual/gender minorities, rural populations, individuals with low socioeconomic status, and those who are incarcerated or homeless.
Examples of research objectives can be found in the calltext.
Research supported under this NOSI is expected to be relevant to the United States. Projects relying on data or cohorts outside of the U.S. must provide a strong justification for the relevance of the research to the U.S. context.
Deadline: This notice applies to due dates on or after June 5, 2022, and subsequent receipt dates through March 5, 2024.
Funding Opportunity Announcement (FOA): Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
• PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-183- NIH Research Project Grant (Parent R01 Clinical Trial Required)
• PA-20-184 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
• PA-20-200- NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
• PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-194- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• PA-20-196 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection, Notice Number: NOT-AI-22-043, US
The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.
Research Objectives: The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics. Research topics of interest in the presence of HIV will include, but are not limited to:
- Impact of HIV infection on HBV immune tolerance, immune activation/inflammation, and HBV viral persistence.
- Factors critical to induce immune control of HBV.
- Viral mechanisms and immune-related factors predictive of HBV reactivation.
- Mechanism for cccDNA biogenesis and decay.
- Role of integrated HBV DNA in HIV/HBV coinfection.
Therapeutics / Diagnostics
- Blood based biomarkers and non-invasive diagnostic tools as correlates to assess liver injury and indicators of treatment response/,
- In vitro, animal models of infection (includes nonhuman primates) for discovery and development of new agents.
- Assessing valid endpoints in various phases of HBV infection to be applied in treatment studies of new therapeutics.
Although clinical trials are not allowed, use of samples from clinical trials is allowed. Animal research is allowed, to include non-human primates.
Deadline: This notice applies to due dates on or after September 5, 2022, and subsequent receipt dates through May 7, 2025.
Funding Opportunity Announcement (FOA): Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice:
- PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
2022 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer, Prostate Cancer Foundation, REQUEST FOR LETTERS OF INTENT
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
- 3-stage application process: 1. Letter of Intent (LOI), 2. Full application submission upon invitation, 3. Peer review of top applicants ( Zoom-based interview).
- Scope: Large-scale research projects concerning metastatic, lethal prostate cancer over a duration of three years.
The general areas of interest include, but are not limited to the following topics:
- Targeting currently undruggable driver transcription factors
- New mechanisms for inducing cancer cell death including gene and cell therapies
- Quenching the metabolic firestorm of cancer
- Integrating understanding of therapeutic resistance into up-front treatments
- Rigorous characterization of host/lifestyle determinants affecting cancer progression
- Therapy discovery that includes diverse and underserved patient populations is encouraged
- Proposals focused on problems that address prostate cancer lethality with application to other malignancies will be reviewed favorably
Budget: PCF will fund 2-3 of these three-year awards for $5 - $10 Million U.S.D. per award. Up to 10% INDI coverage.
- Teams must be composed of at least five (5) investigators, including two young investigators (requirements in the call text), capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research.
- Teams that name a young investigator as part of senior leadership will be favored.
- Team members must represent a minimum of four (4) non-profit academic research institutions.
- Cross-disciplinary teams that are diverse and inclusive will be favored.
Deadline: June 20, 2022: LOI due (by email), Full Proposals (by invitation only) September 9, 2022, 3:00 p.m. Eastern Daylight Time
Prostate cancer foundation information (pdf)
Huntington’s Disease Society of America (HDSA) NOW ACCEPTING LETTERS OF INTENT FOR THE 2022 HD HUMAN BIOLOGY PROJECT
The Human Biology Project was launched in 2013 with the goal of fostering innovative research in collaboration with HD clinics to better understand the biology of Huntington’s disease as it occurs in humans. HDSA encourages researchers to consider one of HDSA’s Centers of Excellence as a potential collaborator, but applicants may propose to work with any HD clinic around the world.
- 1-2 years of funding to support a scientist working collaboratively with an HD clinic anywhere in the world
- Awards up to $75,000/year ($50,000 salary support and $25,000 research budget)
- Recipient must commit at least 50% effort to the project
- Open to researchers from around the world regardless of position/title
- Preference given to young postdoctoral and clinical investigators (PhD and/or MDs) who are not yet independent
- Innovative ideas from non-scientists will also be accepted and encouraged
- Applications from for-profit institutions are welcome
Deadline: May 6, 2022 (LOI), July 8, 2022 (Complete application)